Production (Stage)
Conduit Pharmaceuticals Inc.
CDT
$2.33
-$0.14-5.67%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 84.98% | 130.59% | 112.79% | 63.56% | 61.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 143.27% | 186.32% | 179.82% | 66.96% | 65.41% |
| Operating Income | -143.27% | -186.32% | -179.82% | -66.96% | -65.41% |
| Income Before Tax | -595.70% | -1,860.57% | -258.69% | 22.29% | 55.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -595.70% | -1,860.57% | -258.69% | 22.29% | 55.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -595.70% | -1,860.57% | -258.69% | 22.29% | 55.41% |
| EBIT | -143.27% | -186.32% | -179.82% | -66.96% | -65.41% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -388.34% | -1,345.96% | -150.92% | 46.96% | 67.22% |
| Normalized Basic EPS | -391.48% | -1,342.62% | -135.92% | 48.35% | 68.32% |
| EPS Diluted | -64.19% | -139.65% | -107.08% | -1.69% | 4.50% |
| Normalized Diluted EPS | -392.43% | -1,364.99% | -136.98% | 47.74% | 68.34% |
| Average Basic Shares Outstanding | 138.73% | 29.44% | 24.46% | 33.53% | 85.07% |
| Average Diluted Shares Outstanding | 135.49% | 27.44% | 24.06% | 33.75% | 87.30% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |